TISSIUM

TISSIUM is a medical device company founded in 2013 that develops biomorphic programmable polymers for tissue reconstruction and repair. The company's proprietary technology platform consists of biocompatible polymer building blocks that can be customized to match tissue-specific requirements while conforming to and integrating with surrounding tissue. TISSIUM currently markets COAPTIUM® CONNECT, the first and only FDA-authorized system for atraumatic sutureless nerve coaptation in peripheral nerve repair, which is commercially available in the United States. The company has received FDA De Novo clearance for its lead product and has completed two clinical studies, with 10 peer-reviewed publications and 26 patent families filed (88 patents granted). TISSIUM's pipeline extends across multiple therapeutic areas including peripheral nerve, cardiovascular, and gastrointestinal applications, with both open surgical and minimally invasive procedure formats. The company operates as a medical device manufacturer with focus on surgical reconstruction solutions for patients with damaged or injured tissue. Regulatory credentials include FDA De Novo authorization and adherence to medical device manufacturing standards.